Tasisulam

立即咨询

Tasisulam

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	519055-62-0
规格:	≥98%

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议
250mg	电议
500mg	电议
1g	电议

产品介绍

理化性质和储存条件

Molecular Weight (MW)	415.11
Formula	C11H6BrCl2NO3S2
CAS No.	519055-62-0
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 83 mg/mL (199.94 mM)
	Water:<1 mg/mL (slightly soluble or insoluble)
	Ethanol: N/A
Synonyms	LY573636, LY 573636, LY-573636, Tasisulam, Tasisulam sodium

实验参考方法

General	In mice bearing the Calu-6 non-small cell lung xenograft model, tasisulam exhibited antitumor efficacy in a dose-dependent way and reduced tumor volume by 77%. Tasisulam caused G2-M accumulation and increased nuclear fragmentation. Also, tasisulam induced vascular normalization.
Animal model	Calu-6 non–small cell lung xenograft model
Formulation	saline
Dosages	50 mg/kg
Administration	i.v.
References	[1] Meier T, et al. Mol Cancer Ther. 2011, 10(11), 2168-2178.

生物活性

In vitro effects of tasisulam on endothelial and adipose-derived stem cells. Mol Cancer Ther. 2011 Nov;10(11):2168-78.

Effects of tasisulam on blood vessel formation in vivo. Mol Cancer Ther. 2011 Nov;10(11):2168-78.

Tasisulam displays dose-dependent antitumor activity, induces apoptosis, and normalizes tumor-associated vasculature in the Calu-6 non–small cell lung xenograft model. Mol Cancer Ther. 2011 Nov;10(11):2168-78.